Drug Profile
Recombinant human mannose-binding lectin - NatImmune/Enzon
Alternative Names: rhMBL; rhMBL - NatImmune/EnzonLatest Information Update: 29 Dec 2021
Price :
$50
*
At a glance
- Originator NatImmune
- Developer Enzon Pharmaceuticals; NatImmune
- Class Anti-infectives; Immunotherapies
- Mechanism of Action Complement activation stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Infections
Most Recent Events
- 11 Feb 2009 Discontinued - Phase-I for Infections in United Kingdom (IV)
- 11 Feb 2009 Discontinued - Phase-I/II for Infections in USA (IV)
- 13 Mar 2008 Recombinant human mannose-binding lectin (rhMBL) is still in phase I/II trials for prevention of infections in the US